HIV therapies and the kidney: Some good, some not so good?

Current HIV/AIDS Reports

Volumn 9, Issue 2, 2012, Pages 111-120

  Ryom, Lene ^a   Mocroft, Amanda ^b   Lundgren, Jens ^a,c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Research Department of Infection and Population Health   (United Kingdom)

^c Rigshospitalet   (Denmark)

Author keywords

Abacavir; Adverse events; AKI; Atazanavir; CART; CKD; EGFR; Guidelines; HIV; Indinavir; Kidney disease; Lopinavir; Nephrotoxicity; Pathology; Renal Impairment; Ritonavir; Tenofovir; Tubular dysfunction; Urolithiasis

Indexed keywords

ABACAVIR; ATAZANAVIR; CREATININE; INDINAVIR; LOPINAVIR; MITOCHONDRIAL DNA; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; PHOSPHATE; RITONAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CRYSTALLURIA; DEHYDRATION; DISEASE SEVERITY; DRESS SYNDROME; DRUG CYTOTOXICITY; DRUG ELIMINATION; DRUG SAFETY; FANCONI RENOTUBULAR SYNDROME; FOLLOW UP; GENETIC POLYMORPHISM; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY MASS; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE; KIDNEY TUBULE NECROSIS; META ANALYSIS (TOPIC); MITOCHONDRIAL DNA DEPLETION; NEPHROGENIC DIABETES INSIPIDUS; NEPHROLITHIASIS; NEPHROTOXICITY; PHOSPHATE BLOOD LEVEL; PROTEINURIA; REHYDRATION; RISK FACTOR; TUBULAR DYSFUNCTION; UROLITHIASIS; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY; KIDNEY DISEASE; REVIEW;

ANTI-RETROVIRAL AGENTS; HIV INFECTIONS; HUMANS; KIDNEY; KIDNEY DISEASES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84864023637     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-012-0110-3     Document Type: Article

References (100)

1. Alsauskas ZC, Medapalli RK, Ross MJ. Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients. Expert Opin Pharmacother. 2011;12:691-704.
2. Lima VD, Hogg RS, Harrigan PR, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS. 2007;21:685-92. (Pubitemid 46568625)
3. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS. 2008;22:2409-18.
4. Moreno-Cuerda VJ, Morales-Conejo M, Rubio R. Antiretroviral treatment associated life-threatening adverse events. Med Clin (Barc). 2006;126:744-9. (Pubitemid 43967210)
5. Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with teno-fovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr. 2004;37:1489-95. (Pubitemid 39602339)
6. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-96. (Pubitemid 44837777)
7. Neuhaus J, Mocroft A, Wyatt C, Ross M. Predictors of chronic kidney disease: SMART Trial, Poster837. In: CROI. Boston, USA; 2011.
8. Barraclough K, Er L, Ng F, et al. A comparison of the predictive performance of different methods of kidney function estimation in a well-characterized HIV-infected population. Nephron Clin Pract. 2009;111:c39-48.
9. Menezes AM, Torelly Jr J, Real L, et al. Prevalence and risk factors associated to chronic kidney disease in HIV-Infected patients on HAART and undetectable viral load in Brazil. PLoS One. 2011;6:e26042.
10. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089-100. (Pubitemid 41623371)
11. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23:689-96.
12. Young B, Buchacz K, Baker RK, et al. Renal function in Tenofovir-exposed and Tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Outpatient Study. J Int Assoc Physicians AIDS Care (Chic). 2007;6:178-87.
13. Mocroft A. The difficulties of classifying renal disease in HIV-infected patients. HIV Med. 2011;12:1-3.
14. Schwartz EJ, Szczech LA, Ross MJ, et al. Highly active antiretroviral therapy and the epidemic of HIV+end-stage renal disease. J Am Soc Nephrol. 2005;16:2412-20. (Pubitemid 41725059)
15. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efa-virenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010;55:49-57.
16. Choi AI, Shlipak MG, Hunt PW, et al. HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy. AIDS. 2009;23:2143-9.
17. Campbell LJ, Hamzah L, Post FA. Is tenofovir-related renal toxicity incompletely reversible? J Acquir Immune Defic Syndr. 2011;56:e95. author reply e95-96.
18. Izzedine H, Isnard-Bagnis C, Hulot JS, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS. 2004;18:1074-6. (Pubitemid 38591202)
19. Izzedine H, Launay-Vacher V, Deray G Antiviral drug-induced nephrotoxicity. Am J Kidney Dis. 2005;45:804-17. (Pubitemid 43181039)
20. Harris M. Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients. Expert Opin Drug Saf 2008;7:389-400.
21. Lee JC, Marosok RD. Acute tubular necrosis in a patient receiving tenofovir. AIDS. 2003;17:2543-4. (Pubitemid 38393331)
22. Szczech LA. Renal dysfunction and tenofovir toxicity in HIV-infected patients. Top HIV Med. 2008;16:122-6.
23. Wyatt CM, Klotman PE. Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection. Expert Opin Drug Saf. 2006;5:275-87. (Pubitemid 43379625)
24. Hanabusa H, Tagami H, Hataya H. Renal atrophy associated with long-term treatment with indinavir. N Engl J Med. 1999;340:392-3. (Pubitemid 29090811)
25. Rodriguez-Novoa S, Alvarez E, Labarga P, et al. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf. 2010;9:545-59.
26. Schmid S, Opravil M, Moddel M, et al. Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies. Virchows Arch. 2007;450:665-70. (Pubitemid 46986233)
27. Corsini A. The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovasc Drugs Ther. 2003;17:265-85. (Pubitemid 37421744)
28. Dauchy FA, Lawson-Ayayi S, de La Faille R, et al. Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney Int. 2011;80:302-9.
29. Kalyesubula R, Perazella MA. Nephrotoxicity of HAART. AIDS Res Treat. 2011;2011:562790.
30. Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis. 2006;42:283-90. (Pubitemid 43054205)
31. Antoniou T, Raboud J, Chirhin S, et al. Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med. 2005;6:284-90. (Pubitemid 41025294)
32. Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant. 2005;20:743-6. (Pubitemid 40520651)
33. Kohler JJ, Hosseini SH, Hoying-Brandt A, et al. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest. 2009;89:513-9.
34. Lebrecht D, Venhoff AC, Kirschner J, et al. Mitochondrial tubul-opathy in tenofovir disoproxil fumarate-treated rats. J Acquir Immune Defic Syndr. 2009;51:258-63.
35. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis. 2002;40:1331-3. (Pubitemid 35403147)
36. Rollot F, Nazal EM, Chauvelot-Moachon L, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis. 2003;37:e174-6.
37. Wyatt CM, Winston J. Renal disease in patients with HIV. Curr Infect Dis Rep. 2006;8:76-81. (Pubitemid 43154245)
38. Irizarry-Alvarado JM, Dwyer JP, Brumble LM, et al. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases. AIDS Read. 2009;19:114-21.
39. Fux CA, Simcock M, Wolbers M, et al. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther. 2007;12:1165-73.
40. Deti EK, Thiebaut R, Bonnet F, et al. Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France. HIV Med. 2010;11:308-17.
41. Morlat P VA, Dauchy F, et al. Antiretroviral drugs and incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort (2004-2008) In: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Edited by WEPDB0104 A. Rome, Italy; 2011.
42. Heffelfinger J HD, Voetsch A, et al. Renal impairment associated with the use of tenofovir, Poster 779. In: CROI. Denver; 2006.
43. Scherzer R MME, Li Yet al. Association of tenofovir exposure with kidney disease risk in HIV-infection. TH-OR064 In: J Am Soc Nephrol. 22; 2011.
44. Campo R DE, Khanlou H, et al. SWIFT Study: switching from Lamivudine/Abacavir (3TC/ABC) to Emtricitabine/Tenofovir DF (FTC/TDF), Abstract H2-786. In: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2011.
45. Rho M, Perazella MA. Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients. Curr Drug Saf 2007;2:147-54. (Pubitemid 46805547)
46. Brennan A, Evans D, Maskew M, et al. Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS. 2011;25:1603-9.
47. *5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568-79.
48. Ahmad M. Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome. J Postgrad Med. 2006;52:296-7. (Pubitemid 44862772)
49. Flandre P, Pugliese P, Cuzin L, et al. Risk factors of chronic kidney disease in HIV-infected patients. Clin J Am Soc Nephrol. 2011;6:1700-7. New AIDS data.
50. Daugas E, Rougier JP, Hill G. HAART-related nephropathies in HIV-infected patients. Kidney Int. 2005;67:393-403. (Pubitemid 40139831)
51. Nelson M, Azwa A, Sokwala A, et al. Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy. AIDS. 2008;22:1374-6.
52. Rockwood N, Mandalia S, Bower M, et al. Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir. AIDS. 2011;25:1671-3.
53. Knudtson E, Para M, Boswell H, et al. Drug rash with eosino-philia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus. Obstet Gynecol. 2003;101:1094-7. (Pubitemid 36566389)
54. Harris M MH, YIB B, et al. Hyoposphatemia and albuminuria are associated with older age in HIV+adults receiving ART, Abstract P-01. In: 2nd international workshop on HIV and ageing. Baltimore, USA; 2011.
55. Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010;24:1667-78.
56. Kopp JB, Falloon J, Filie A, et al. Indinavir-associated interstitial nephritis and urothelial inflammation: clinical and cytologic findings. Clin Infect Dis. 2002;34:1122-8. (Pubitemid 34289686)
57. Chugh S, Bird R, Alexander EA. Ritonavir and renal failure. N Engl J Med. 1997;336:138.
58. Doco-Lecompte T, Garrec A, Thomas L, et al. Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases. AIDS. 2004;18:705-6. (Pubitemid 38393477)
59. Feicke A, Rentsch KM, Oertle D, et al. Same patient, new stone composition: amprenavir urinary stone. Antivir Ther. 2008;13:733-4.
60. Engeler DS, John H, Rentsch KM, et al. Nelfinavir urinary stones. J Urol. 2002;167:1384-5. (Pubitemid 34132100)
61. Green ST, McKendrick MW, Schmid ML, et al. Renal calculi developing de novo in a patient taking saquinavir. Int J STD AIDS. 1998;9:555. (Pubitemid 28423490)
62. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175-85. (Pubitemid 36618128)
63. Izzedine H, Harris M, Perazella MA. The nephrotoxic effects of HAART Nat Rev Nephrol. 2009;5:563-73.
64. Gupta SK. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS. 2008;22:99-103. (Pubitemid 351252586)
65. Crum-Cianflone N, Ganesan A, Teneza-Mora N, et al. Prevalence and factors associated with renal dysfunction among HIV-infected patients. AIDS Patient Care STDS. 2010;24:353-60.
66. Roe J, Campbell LJ, Ibrahim F, et al. HIV care and the incidence of acute renal failure. Clin Infect Dis. 2008;47:242-9. (Pubitemid 351920627)
67. Peraldi MN, Maslo C, Akposso K, et al. Acute renal failure in the course of HIV infection: a single-institution retrospective study of ninety-two patients anad sixty renal biopsies. Nephrol Dial Transplant. 1999;14:1578-85. (Pubitemid 29241763)
68. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007;21:1273-81. (Pubitemid 46883481)
69. Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother. 2006;50:3297-304. (Pubitemid 44527501)
70. Kohler JJ, Hosseini SH, Green E, et al. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Invest. 2011;91:852-8.
71. Van Rompay KK, Brignolo LL, Meyer DJ, et al. Biological effects of short-term or prolonged administration of 9-[2-(phos-phonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother. 2004;48:1469-87. (Pubitemid 38544348)
72. Cote HC, Magil AB, Harris M, et al. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy. Antivir Ther. 2006;11:79-86.
73. Cihlar T, Birkus G, Greenwalt DE, et al. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antiviral Res. 2002;54:37-45. (Pubitemid 34219173)
74. Kiser JJ, Carten ML, Aquilante CL, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther. 2008;83:265-72.
75. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS. 2002;16:1257-63. (Pubitemid 34666660)
76. Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr. 2004;35:269-73. (Pubitemid 38280652)
77. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovu-dine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr. 2008;47:74-8. (Pubitemid 351619372)
78. Horberg M, Tang B, Towner W, et al. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2010;53:62-9.
79. Fux C. Tenofovir and PI use are associated with an increased prevalence of proximal renal tubular dysfunction in the Swiss HIV Cohort Study. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections Montréal, Canada.; 2009.
80. Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51:496-505.
81. A Avihingsanon KP, J Wongsabut, et al. HIVNAT 006 Study team prevalence and prognostic factors of chronic kidney disease in HIV-infected patients, HIV-NAT 006 Cohort, Thailand, poster 843. In: CROI. Boston; 2011.
82. Gallant JE, Parish MA, Keruly JC, et al. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis. 2005;40:1194-8. (Pubitemid 40490248)
83. Buchacz K, Brooks JT, Tong T, et al. Evaluation of hypophos-phataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy. HIV Med. 2006;7:451-6. (Pubitemid 44269812)
84. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201. (Pubitemid 38917996)
85. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-60. (Pubitemid 43113030)
86. Gallant JE, Winston JA, DeJesus E, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS. 2008;22:2155-63.
87. Mocroft A, Kirk O, Gatell J, et al. Chronic renal failure among HIV-1-infected patients. AIDS. 2007;21:1119-27. (Pubitemid 46763282)
88. Arnaiz JA, Mallolas J, Podzamczer D, et al. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS. 2003;17:831-40. (Pubitemid 36547655)
89. Dragsted UB, Gerstoft J, Pedersen C, et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J Infect Dis. 2003;188:635-42. (Pubitemid 37115175)
90. Brewster UC, Perazella MA. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis. 2004;44:e81-4. (Pubitemid 39445931)
91. Chang HR, Pella PM. Atazanavir urolithiasis. N Engl J Med. 2006;355:2158-9.
92. Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis. 2011;204:1191-201.
93. Albini L, Cesana BM, Motta D, et al. A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz. J Acquir Immune Defic Syndr. 2012;59:18-30.
94. Duong M, Sgro C, Grappin M, et al. Renal failure after treatment with ritonavir. Lancet. 1996;348:693.
95. Chan-Tack KM, Truffa MM, Struble KA, et al. Atazanavir-associated nephrolithiasis: cases from the US food and drug administration's adverse event reporting system. AIDS. 2007;21:1215-8. (Pubitemid 46763296)
96. Reilly RF, Tray K, Perazella MA. Indinavir nephropathy revisited: a pattern of insidious renal failure with identifiable risk factors. Am J Kidney Dis. 2001;38:E23.
97. Wever K, van Agtmael MA, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr. 2010;55:78-81.
98. Bredeek F GR, Yolo R, Schneider S. A switch from TDF/FTC to raltegravir in patients on a boosted protease inhibitor is effective in reducing proteinuria and increasing GFR, Abstract H1-1399b. In: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, USA; 2011.
99. Kowalska JD, Kirk O, Mocroft A, et al. Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-1-infected patients treated with abacavir. HIV Med. 2010;11:200-8.
100. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV medicine association of the infectious diseases society of America. Clin Infect Dis. 2005;40:1559-85. (Pubitemid 40720806)